Introduction：Basic information about CAS 158966-92-8|Montelukast, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Montelukast |
|---|
| CAS Number | 158966-92-8 | Molecular Weight | 586.183 |
|---|
| Density | 1.3±0.1 g/cm3 | Boiling Point | 750.5±60.0 °C at 760 mmHg |
|---|
| Molecular Formula | C35H36ClNO3S | Melting Point | / |
|---|
| MSDS | / | Flash Point | 407.7±32.9 °C |
|---|
Names
| Name | montelukast |
|---|
| Synonym | More Synonyms |
|---|
Montelukast BiologicalActivity
| Description | Montelukast is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage[1]. |
|---|
| Related Catalog | Signaling Pathways >>GPCR/G Protein >>Leukotriene ReceptorResearch Areas >>Inflammation/Immunology |
|---|
| Target | CysLT1 |
|---|
| In Vitro | Montelukast (5 μM; 1 h) inhibits APAP-induced cell damage[1]. |
|---|
| In Vivo | Montelukast (3 mg/kg; oral gavage) protects against APAP-induced hepatotoxicity in mice[1]. Montelukast (1 mg/kg; miniosmotic pump administration) reduces the airway remodeling changes observed in OVA-treated mice and blocks the actions of cysteinyl leukotrienes (LT) C4, D4, and E4 mediated by the CysLT1 receptor[2]. Montelukast (1 mg/kg; miniosmotic pump administration) reduces the elevated levels of IL-4 and IL-13 found in the BAL fluid of OVA-treated mice[2]. Animal Model: C57BL/6J mice (8-week-old; 22-25 g) are induced acute hepatic injury[1] Dosage: 3 mg/kg Administration: Oral gavage 1 h after saline or APAP administration Result: Decreased serum levels of alanine transaminase (ALT) and aspartate aminotransferase (AST), and alleviated liver damage. |
|---|
| References | [1]. Pu S, et, al. Montelukast Prevents Mice Against Acetaminophen-Induced Liver Injury. Front Pharmacol. 2019 Sep 18; 10:1070. [2]. William RHJ, et, al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med. 2002 Jan 1; 165(1): 108-16. |
|---|
Chemical & Physical Properties
| Density | 1.3±0.1 g/cm3 |
|---|
| Boiling Point | 750.5±60.0 °C at 760 mmHg |
|---|
| Molecular Formula | C35H36ClNO3S |
|---|
| Molecular Weight | 586.183 |
|---|
| Flash Point | 407.7±32.9 °C |
|---|
| Exact Mass | 585.210449 |
|---|
| PSA | 95.72000 |
|---|
| LogP | 7.80 |
|---|
| Vapour Pressure | 0.0±2.6 mmHg at 25°C |
|---|
| Index of Refraction | 1.678 |
|---|
| InChIKey | UCHDWCPVSPXUMX-TZIWLTJVSA-N |
|---|
| SMILES | CC(C)(O)c1ccccc1CCC(SCC1(CC(=O)O)CC1)c1cccc(C=Cc2ccc3ccc(Cl)cc3n2)c1 |
|---|
| Storage condition | 2-8°C |
|---|
Safety Information
Synonyms
| Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- |
| [3H]-Montelukast |
| Brondilat (TN) |
| Montelukast |
| (1-{1-{3(R)-[2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-3-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-propylsulfanylmethyl}-cyclopropyl)-acetic acid |
| {1-[({(1R)-1-{3-[(E)-2-(7-Chloroquinolin-2-yl)vinyl]phenyl}-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid |
| Montair |
| 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid |
| Singular |
| [R-(E)]-1-[[[1-[3-[2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic Acid |
| {1-[({(1R)-1-{3-[(E)-2-(7-Chloro-2-quinolinyl)vinyl]phenyl}-3-[2-(2-hydroxy-2-propanyl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid |
| Montelukast [INN:BAN] |
| MFCD05662278 |
| Montelukast (INN) |
| {1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid |
| [14C]-Montelukast |
| UNII-MHM278SD3E |
